Minicircle system technology originators

Minicircle is a clinical-stage biotechnology company developing a novel class of reversible gene therapies based on its proprietary minicircle DNA platform. Unlike traditional viral vectors or permanent gene edits, the company's non-viral DNA vectors are designed to be long-lasting yet episomal, allowing for dose-titration and complete reversal via a small-molecule off-switch. Their lead program, a follistatin-encoding minicircle, is currently in Phase 1 clinical trials for the treatment of muscle wasting and as a longevity intervention. The company has gained significant attention for its innovative regulatory approach, conducting trials in the Próspera ZEDE in Honduras, and is backed by prominent technology investors including Peter Thiel and Sam Altman.